Monday, March 25, 2019 8:39:14 AM
Yes, last weeks trial results were terrible but but but they did nothing to negate the earlier trial results that did show positive and significant positives from taking the drug. And I know that technically those trials "failed" but the reality is that a lot of good things were learned in those trials.
The clear value for emricasan RIGHT NOW is in combination with other drugs. That has value and is worth something far more than current market cap. It could also change with the upcoming hypertension trial results and LF conclusions.
They are "on base" with the earlier trial results. They struck out with the latest. But they still have two big swings upcoming.
And my belief is even if the next two swings are misses, the drug has proven enough for Novartis to want it and take the entire company in the process. No way will Conatus raise money with a sub-$2 stock.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM